Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.

Author: BisoiDebasis, ChaliserryLeo Francis, EerikeMadhavi, JantiSiddharam S, MaliKalpana Ramanna, PriyadarshiniRekha, RajGerard Marshall, RaviGandham

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic review evaluated the safety and efficacy of molnupiravir for the treatment of mild COVID-19. Molnupiravir was safe and well-tolerated, with common adverse effects including nausea, diarrhea, and headache. It significantly decreased time to viral clearance and reduced the risk of hospitalization or death in high-risk patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Molnupiravir is an oral antiviral drug that received Emergency Use Authorization in three countries for the treatment of mild COVID-19. The aim of this systematic review was to find out the safety and efficacy of Molnupiravir in SARS-COV-2 infections. METHODS: The electronic databases s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463664/

データ提供：米国国立医学図書館（NLM）

Molnupiravir: A Promising New Antiviral for COVID-19

The COVID-19 pandemic has brought a wave of uncertainty and challenges to the world. This research explores the potential of molnupiravir, a novel antiviral drug, to treat mild COVID-19. The study, a systematic review of clinical trials, examined the safety and efficacy of molnupiravir in patients with COVID-19, specifically focusing on its ability to reduce viral clearance time and potentially prevent hospitalization or death.

Molnupiravir: A Potential for Improved COVID-19 Outcomes

The systematic review reveals promising results for molnupiravir in treating mild COVID-19. The study found that molnupiravir, administered at a dose of 1600 mg daily for 5 days, was safe and well-tolerated, with the most common side effects being nausea, diarrhea, and headache. Moreover, the review showed a significant reduction in viral clearance time and a decrease in the risk of hospitalization or death in high-risk mild COVID-19 patients.

Molnupiravir: A New Hope in the Fight Against COVID-19

This research provides compelling evidence for the potential of molnupiravir as a safe and effective treatment option for mild COVID-19. The study's findings suggest that molnupiravir could play a crucial role in managing COVID-19, potentially reducing the severity of the disease and improving patient outcomes. This research highlights the ongoing efforts to develop new and effective treatments for COVID-19 and underscores the importance of exploring novel antiviral therapies to combat this global health challenge.

Dr.Camel's Conclusion

The systematic review offers a glimmer of hope in the fight against COVID-19, suggesting that molnupiravir could be a valuable addition to the treatment arsenal. The research highlights the importance of developing new and effective antiviral therapies to address this global health crisis. Further research is warranted to confirm the long-term efficacy and safety of molnupiravir and its role in managing COVID-19.

Date :
  1. Date Completed 2023-10-23
  2. Date Revised 2023-10-23
Further Info :

Pubmed ID

36087236

DOI: Digital Object Identifier

PMC9463664

Related Literature

Article Analysis
・Side Effects of molnupiravir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.